# Automated Proteomics System

- **Source:** TED · `576112-2025`
- **Buyer:** Københavns Universitet
- **Published:** 2025-09-04
- **Deadline:** —
- **Estimated value:** 447,370 EUR
- **CPV codes:** 38433100
- **Place-of-performance NUTS:** DK011, DNK
- **Buyer-address NUTS:** —
- **Notice type:** can-standard / 29

## Procedure details

Source lists may span several lots; list positions do not establish relationships.

### Procedure Types

- neg-wo-call

### Award Criterion Names

- kun en leverandør mulig

### Award Criterion Descriptions

- Key technical and scientific differentiators that exclude alternative suppliers: • Patent-protected technology: The NULISA™ platform is protected by multiple patents (including US20210278398A1, U.S. Patent No. 12105084, U.S. Patent No. 12188929, and EU Patent EP4069731A1), granting ALAMAR Biosciences exclusive rights to manufacture and distribute the system and its associated technologies. • Fully automated high-throughput platform: The ARGO™ HT integrates all sample preparation and analysis steps within a single instrument, including an embedded qPCR system and support for Next Generation Sequencing (NGS). It enables multiplexed analysis of up to 1,000 protein targets across 96 to 288 samples per run. • High sensitivity and specificity: The system leverages oligonucleotide-conjugated antibodies and a proprietary dual capture-and-release mechanism, which dramatically reduces background noise and delivers highly accurate and reproducible results. • Time efficiency and ease of use: The platform requires less than 30 minutes of hands-on time, with singleplex results available in under 6 hours, and multiplex results in under 15 hours, making it one of the most efficient solutions currently available.

## Description

The purpose of the acquisition of the ARGO™ HT System is to expand the service portfolio of the Proteomics Research Infrastructure (PRI) by implementing NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology, which enables highly sensitive proteomic analyses and the precise quantification of low-abundance biomarkers complementary to existing proteomic pipelines at PRI. The ARGO™ HT System is a technologically unique platform based on the patented NULISA™ technology, which enables ultra-sensitive protein detection at attomolar concentrations—a level of sensitivity unattainable with conventional proteomics platforms.

## Award result

- **Published notice total:** 447,370 EUR
- **Contract concluded:** 2025-09-01
- **Winner:** Alamar Biosciences Europe Srl (CVR 13467230960) · value 447,370 EUR
Published values may cover multiple lots, options and frameworks; they are not supplier revenue. Unlinked notice summaries do not assign each value or expiry to each winner.

## Original notice

https://ted.europa.eu/da/notice/-/detail/576112-2025